<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40388785</article-id><article-id pub-id-type="pmc">PMC12091674</article-id>
<article-id pub-id-type="publisher-id">MD-D-24-11728</article-id><article-id pub-id-type="art-access-id">00066</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000042306</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>3400</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Impact of ejection fraction changes on long-term outcomes in VA-ECMO patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Cheng-Ta</given-names></name><degrees>MD</degrees><email>dazandy@gmail.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Yu-Ting</given-names></name><degrees>MD</degrees><email>cooltony@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Yi-Hsin</given-names></name><degrees>MD</degrees><email>S851047@hotmail.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Victor Chien-Chia</given-names></name><degrees>MD</degrees><email>victorcwu@hotmail.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Dong-Yi</given-names></name><degrees>MD</degrees><email>josephchen0314@gmail.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Hung</surname><given-names>Kuo-Chun</given-names></name><degrees>MD</degrees><email>0062@cgmh.org.tw</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Hsiao</surname><given-names>Fu-Chih</given-names></name><degrees>MD</degrees><email>maniclone@gmail.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Tung</surname><given-names>Ying-Chang</given-names></name><degrees>MD</degrees><email>n12374@cgmh.org.tw</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Chia-Pin</given-names></name><degrees>MD</degrees><email>chiapinlin@hotmail.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Chu</surname><given-names>Pao-Hsien</given-names></name><degrees>MD</degrees><email>Taipei.chu@gmail.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Shao-Wei</given-names></name><degrees>MD, PhD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Medical Education, Chang Gung University, Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan</aff><aff id="aff2"><label>b</label>Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City, Taiwan</aff><aff id="aff3"><label>c</label>Department of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City, Taiwan</aff><aff id="aff4"><label>d</label>Department of Medical Research and Development, Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Shao-Wei Chen, Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, No. 5 Fuxing Street, Guishan District, Taoyuan City 33305, Taiwan (e-mail: <email xlink:href="josephchen0314@gmail.com">josephchen0314@gmail.com</email>).</corresp></author-notes><pub-date pub-type="collection"><day>16</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2025</year></pub-date><volume>104</volume><issue>20</issue><elocation-id>e42306</elocation-id><history><date date-type="received"><day>28</day><month>9</month><year>2024</year></date><date date-type="received"><day>19</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="medi-104-e42306.pdf"/><abstract><p>There is limited evidence regarding the association between myocardial function requiring extracorporeal membrane oxygenation (ECMO) and long-term survival rate in patients who reach hospital discharge. This study investigates the association between myocardial function parameters collected at different times from weaning from ECMO to long-term follow-up and the long-term mortality rate. This retrospective study investigates the effect of EF timing in the long-term. A cohort of 403 patients successfully weaned from veno-arterial ECMO (VA-ECMO) was identified from 1300 patients who underwent VA-ECMO between 2003 and 2018 after applying exclusion criteria for age and indications not of interest in the Chang Gung Memorial Hospital Research Database (CGRD). The study revealed that a notable improvement in ejection fraction (EF) percentile between ECMO placement and successful weaning was significantly linked to reduced cumulative mortality as were higher EF values before discharge. However, no significant association was found between lower long-term mortality and EF change from discharge to mid-term follow-up, or the maximum EF at mid-term follow-up. Improvements in cardiac function following the use of VA-ECMO and better baseline cardiac function are associated with lower long-term mortality. The study showed that EF monitoring at ECMO insertion and before discharge can inform physicians regarding patients&#x02019; long-term outcomes. EF percentile improvement from insertion to weaning could be a positive indicator of successful weaning.</p></abstract><kwd-group><kwd>ECMO</kwd><kwd>long myocardial function</kwd><kwd>term follow up</kwd><kwd>VA</kwd></kwd-group><funding-group><award-group id="ID0EFNAG133864"><funding-source><institution-wrap><institution>Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital</institution><institution-id institution-id-type="doi">10.13039/100017667</institution-id></institution-wrap></funding-source><award-id>CFRPG3N0011(YTC)</award-id><principal-award-recipient>Shao-Wei Chen</principal-award-recipient></award-group><award-group id="ID0EYTAG133865"><funding-source><institution-wrap><institution>National Science and Technology Council</institution><institution-id institution-id-type="doi">10.13039/100020595</institution-id></institution-wrap></funding-source><award-id>NSTC-112-2314-B-182A-107</award-id><principal-award-recipient>Shao-Wei Chen</principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>
1. Introduction</title><p>Extracorporeal membrane oxygenation (ECMO) provides hemodynamic stability in patients with severe cardiopulmonary dysfunction. Veno-arterial ECMO (VA-ECMO) has been increasingly implemented during extracorporeal cardiopulmonary resuscitation in emergency settings as first-line circulatory support<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> and as a bridge to myocardial recovery<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> in cardiogenic shocks (CSs) and post-cardiotomy shocks.</p><p>By providing oxygenated blood flow to the failing heart, VA-ECMO allows hemodynamic stability and influences left ventricular function throughout the intervention. Basal left ventricle (LV) function during weaning is important in determining myocardial recovery and mid-term survival.<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>]</sup> However, the role of the dynamic changes in ejection fraction (EF) during VA-ECMO support remains to be investigated. Moreover, there is limited data on the long-term follow-up of patients who survive discharge due to high mortality and loss of follow-up. While Wu et al, previously identified a significantly worse short-to-mid-term survival in post-cardiotomy shock resuscitation with postoperative LVEF&#x02005;&#x0003c;&#x02005;30% using the database from our medical center, there is no further data on patients with other indications.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> In addition, despite identifying an association between EF&#x02005;&#x0003e;&#x02005;30% at weaning and significantly improved survived to discharge outcomes,<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> there is no current data on a more detailed dynamic change in EF at weaning, before discharge, and during follow-up for patients with indications from post-cardiotomy shock, extracorporeal cardiopulmonary resuscitation (ECPR), and cardiogenic shock (CS). Furthermore, there is little evidence regarding the association between these parameters and long-term mortality.</p><p>We aimed to provide a comprehensive analysis of the effects of changes in myocardial function and its absolute baseline values at different time points on the long-term outcome, to improve the clinical use of EF for physicians guiding both weaning strategies and managing follow-up in patients who survive to discharge. This paper mainly focuses on VA-ECMO, myocardial function at different times, and long-term survival outcomes.</p></sec><sec sec-type="methods"><title>
2. Methods</title><sec><title>
2.1. Data source</title><p>Study data were collected routinely from the electronic medical records of the Chang Gung Research Database (CGRD) of the Chang Gung Memorial Hospitals (CGMH) between 2003 and 2018. The CGMH system contains 3 medical centers and 4 regional hospitals with over 9000 beds and 30,000 outpatients daily, one of the largest medical systems in Asia. The multi-institutional electronic medical record database has been used for real-world retrospective studies in Taiwan, containing detailed clinical data, including claims data for insurance purposes, operation notes (free-typing text), discharge records (free-typing text), and pathological and laboratory results.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> Encrypted digital medical records have been in use for over 20 years and are unlabeled for research purposes while protecting patients&#x02019; privacy. The study received ethical and administrative approval from the Institutional Review Board of CGMH (202100124B0). Informed consent for participants was waived.</p></sec><sec sec-type="subjects"><title>
2.2. Study design and patient identification</title><p>This was designed as a retrospective cohort study of VA-ECMO data collected between 2003 and 2018 in the CGRD. The data of VA-ECMO were ascertained by manually examining the operation notes (surgical reports) and 1300 patients administered VA-ECMO were identified. The exclusion criteria were patients under 18 years of age (n&#x02005;=&#x02005;127), those who received a heart transplant or ventricular assist device (VAD) (n&#x02005;=&#x02005;22) during admission, and those with indications for diseases other than primary cardiac disease (n&#x02005;=&#x02005;252), including septic shock, pulmonary embolism, social indications, and others (Fig. <xref rid="F1" ref-type="fig">1</xref>). Indications were judged based on operation notes and discharge notes. 899 patients with indications of interest were included, including post-cardiotomy shock, myocarditis, acute myocardial infarction (AMI), ventricular tachycardia (VT) or ventricular fibrillation, decompensated heart failure, and ECPR. The remaining 899 patients were classified into the weaned (n&#x02005;=&#x02005;624) and failed weaning (n&#x02005;=&#x02005;275) groups. The time frame for successful weaning was set to a survival of more than 24 hours after weaning to decannulation. Among the 624 weaned patients, 403 survivors were included in further analysis of the association between LVEF, LVEF change, and mortality risk (Fig. <xref rid="F1" ref-type="fig">1</xref>).</p><fig position="float" id="F1"><label>Figure 1.</label><caption><p>The flowchart for the inclusion and exclusion of the study patients. AMI = acute myocardial infarction, ECMO = extracorporeal membrane oxygenation, ECPR = extracorporeal cardiopulmonary resuscitation, HF = heart failure, VA = veno-arterial, VF = ventricular fibrillation, VT = ventricular tachycardia.</p></caption><graphic xlink:href="medi-104-e42306-g001" position="float"/></fig></sec><sec><title>
2.3. extracorporeal membrane oxygenation flow rates and turn-down study</title><p>The initial mode after ECMO insertion is full support mode, with the ECMO flow target cardiac indexed at 2.0&#x02009;L/min/m<sup>2</sup>, adjusted accordingly based on parameters such as lactate and central vein saturation. There was a turndown study during heart function recovery, the flow was gradually decreased from 1.5 to 1&#x02009;L/min and then to 0.5&#x02009;L/min at weaning. We kept track of relevant parameters: LVEF, aortic velocity-time integral, and lateral mitral annulus peak systolic velocity. We combined them with ECHO parameters and the inotropic score to assess the decision to remove ECMO.</p></sec><sec><title>
2.4. Ejection fraction and outcome</title><p>The study outcome was all-cause mortality after discharge. Patients were followed from the day of discharge to the day of death or December 31, 2018, whichever came first. Only deaths occurring within the hospital system or among patients with out-of-hospital cardiac arrest who were brought to the facility could be identified. The exposure variables in this study were LVEF according to different definitions. The first definition was an improvement from the perioperative period (before ECMO insertion) to before discharge (available number&#x02005;=&#x02005;102). The second definition was LVEF before discharge (available number&#x02005;=&#x02005;238). The third definition was an improvement from discharge to the 180<sup>th</sup> day after discharge (available number&#x02005;=&#x02005;88). The fourth definition was LVEF as the 180<sup>th</sup> day after discharge (available number&#x02005;=&#x02005;177). Echocardiography closest (&#x000b1; 90 days) to the 180<sup>th</sup> day after discharge was selected for analysis.</p></sec><sec><title>
2.5. Covariates</title><p>Covariates included baseline characteristics and ECMO-related features. Baseline characteristics include demographics (age, sex, body mass index, and smoking), comorbidities (diabetes, hypertension, and 14 others), Charlson comorbidity index (CCI) total score, and preoperative laboratory data (hemoglobin, serum creatinine, and 9 others). ECMO-related features include indications, duration from admission to ECMO insertion, flow rate, turn rate, oxygen flow, peripheral/central, and perioperative treatments, including intra-aortic balloon pump, percutaneous coronary intervention (PCI), percutaneous transluminal coronary angioplasty, and coronary artery bypass graft. Comorbidities and CCI scores were extracted using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) before 2016, and the Tenth Revision (ICD-10-CM) in and after 2016. Laboratory data were captured at the time closest to the surgery, always within 24 hours.</p></sec><sec><title>
2.6. Statistics</title><p>The baseline characteristics and ECMO-related features of the patients who died during admission vs those who survived discharge were compared using an independent sample t-test for continuous variables or the chi-square test for categorical variables. The trend of the proportions of in-hospital deaths across the study years (2003&#x02013;2018) was assessed using the Cochran&#x02013;Armitage test. The trend of LVEF values across ECMO insertion, before discharge, and the 180<sup>th</sup> day after discharge was tested using a generalized estimating equation (with identity linking function and normal distribution), in which the analyzed cohort was restricted to the 403 patients who survived to discharge. LVEF values with the 4 definitions were categorized into 2 or 3 groups, as appropriate. The risk of all-cause mortality between the groups (e.g., LVEF before discharge: &#x0003c;30%, 30% to 49%, and&#x02005;&#x02265;&#x02005;50%) was compared using a log-rank test. Owing to the limited sample size, no covariate adjustment was made. Two-sided <italic toggle="yes">P</italic>-values&#x02005;&#x0003c;&#x02005;.05 were considered statistically significant. SAS version 9.4 (SAS Institute) was used for statistical analyses.</p></sec></sec><sec sec-type="results"><title>
3. Results</title><sec><title>
3.1. Epidemiological information</title><p>The distribution of indications for patients who were weaned and survived discharge weaned and died during admission, and failed weaning are listed in Figure <xref rid="F1" ref-type="fig">1</xref>. The number of extracorporeal membrane oxygenation (ECMO) procedures and the proportion of in-hospital deaths increased with year (Fig. <xref rid="F2" ref-type="fig">2</xref>A). The proportion of post-cardiotomy shock decreased over time, while that of AMI and ECPR increased over the years (Fig. <xref rid="F2" ref-type="fig">2</xref>B).</p><fig position="float" id="F2"><label>Figure 2.</label><caption><p>The number of VA-ECMO and proportion of in-hospital deaths across years (A) and the distribution of indications across the study period (B). AMI = acute myocardial infarction, ECMO = extracorporeal membrane oxygenation, ECPR = extracorporeal cardiopulmonary resuscitation, HF = heart failure, VA = veno-arterial, VF = ventricular fibrillation, VT = ventricular tachycardia.</p></caption><graphic xlink:href="medi-104-e42306-g002" position="float"/></fig></sec><sec><title>
3.2. Baseline characteristics</title><p>Of the 899 patients supported with VA-ECMO, the mean age was 58.7 years and 70% (n&#x02005;=&#x02005;627) were male. 45% (n&#x02005;=&#x02005;403) of patients survived to discharge. Compared to patients who died during admission, those who survived discharge were younger and had a lower prevalence of diabetes, coronary artery disease, peripheral artery disease, myocardial infarction, chronic kidney disease, bleeding events, and malignancy. The CCI score was also significantly lower in patients who survived to discharge. Patients who survived to discharge had lower levels of PaCO2, creatinine, liver function markers, and lactic acid but higher pH and platelet count (Table <xref rid="T1" ref-type="table">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics of patients who underwent VA-ECMO by the survival status at discharge.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Available number</th><th align="center" rowspan="1" colspan="1">Total (n&#x02005;=&#x02005;899)</th><th align="center" rowspan="1" colspan="1">In-hospital death (n&#x02005;=&#x02005;496)</th><th align="center" rowspan="1" colspan="1">Survivor to discharge (n&#x02005;=&#x02005;403)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Demographics</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Age, yr</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">58.7&#x02005;&#x000b1;&#x02005;14.9</td><td align="center" rowspan="1" colspan="1">60.7&#x02005;&#x000b1;&#x02005;14.8</td><td align="center" rowspan="1" colspan="1">56.2&#x02005;&#x000b1;&#x02005;14.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">627 (69.7)</td><td align="center" rowspan="1" colspan="1">337 (67.9)</td><td align="center" rowspan="1" colspan="1">290 (72.0)</td><td align="center" rowspan="1" colspan="1">.19</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Body mass index, kg/m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">794</td><td align="center" rowspan="1" colspan="1">25.4&#x02005;&#x000b1;&#x02005;4.6</td><td align="center" rowspan="1" colspan="1">25.5&#x02005;&#x000b1;&#x02005;5.0</td><td align="center" rowspan="1" colspan="1">25.3&#x02005;&#x000b1;&#x02005;4.1</td><td align="center" rowspan="1" colspan="1">.53</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Smoking</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">324 (36.0)</td><td align="center" rowspan="1" colspan="1">178 (35.9)</td><td align="center" rowspan="1" colspan="1">146 (36.2)</td><td align="center" rowspan="1" colspan="1">.92</td></tr><tr><td align="left" colspan="6" rowspan="1">Comorbid conditions</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diabetes</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">295 (32.8)</td><td align="center" rowspan="1" colspan="1">182 (36.7)</td><td align="center" rowspan="1" colspan="1">113 (28.0)</td><td align="center" rowspan="1" colspan="1">.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypertension</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">472 (52.5)</td><td align="center" rowspan="1" colspan="1">276 (55.6)</td><td align="center" rowspan="1" colspan="1">196 (48.6)</td><td align="center" rowspan="1" colspan="1">.04</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chronic obstructive pulmonary disease</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">86 (9.6)</td><td align="center" rowspan="1" colspan="1">53 (10.7)</td><td align="center" rowspan="1" colspan="1">33 (8.2)</td><td align="center" rowspan="1" colspan="1">.21</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Liver cirrhosis</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">29 (3.2)</td><td align="center" rowspan="1" colspan="1">18 (3.6)</td><td align="center" rowspan="1" colspan="1">11 (2.7)</td><td align="center" rowspan="1" colspan="1">.45</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Coronary artery disease</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">528 (58.7)</td><td align="center" rowspan="1" colspan="1">319 (64.3)</td><td align="center" rowspan="1" colspan="1">209 (51.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">152 (16.9)</td><td align="center" rowspan="1" colspan="1">84 (16.9)</td><td align="center" rowspan="1" colspan="1">68 (16.9)</td><td align="center" rowspan="1" colspan="1">.98</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Peripheral artery disease</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">150 (16.7)</td><td align="center" rowspan="1" colspan="1">103 (20.8)</td><td align="center" rowspan="1" colspan="1">47 (11.7)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cerebrovascular accident</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">83 (9.2)</td><td align="center" rowspan="1" colspan="1">54 (10.9)</td><td align="center" rowspan="1" colspan="1">29 (7.2)</td><td align="center" rowspan="1" colspan="1">.06</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Myocardial infarction</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">195 (21.7)</td><td align="center" rowspan="1" colspan="1">128 (25.8)</td><td align="center" rowspan="1" colspan="1">67 (16.6)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hyperlipidemia</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">268 (29.8)</td><td align="center" rowspan="1" colspan="1">149 (30.0)</td><td align="center" rowspan="1" colspan="1">119 (29.5)</td><td align="center" rowspan="1" colspan="1">.87</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chronic kidney disease</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">360 (40.0)</td><td align="center" rowspan="1" colspan="1">252 (50.8)</td><td align="center" rowspan="1" colspan="1">108 (26.8)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastrointestinal bleeding</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">121 (13.5)</td><td align="center" rowspan="1" colspan="1">82 (16.5)</td><td align="center" rowspan="1" colspan="1">39 (9.7)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Major bleeding</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">60 (6.7)</td><td align="center" rowspan="1" colspan="1">41 (8.3)</td><td align="center" rowspan="1" colspan="1">19 (4.7)</td><td align="center" rowspan="1" colspan="1">.03</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gout</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">90 (10.0)</td><td align="center" rowspan="1" colspan="1">57 (11.5)</td><td align="center" rowspan="1" colspan="1">33 (8.2)</td><td align="center" rowspan="1" colspan="1">.10</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Malignancy</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">76 (8.5)</td><td align="center" rowspan="1" colspan="1">53 (10.7)</td><td align="center" rowspan="1" colspan="1">23 (5.7)</td><td align="center" rowspan="1" colspan="1">.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heart failure hospitalization</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">109 (12.1)</td><td align="center" rowspan="1" colspan="1">60 (12.1)</td><td align="center" rowspan="1" colspan="1">49 (12.2)</td><td align="center" rowspan="1" colspan="1">.98</td></tr><tr><td align="left" rowspan="1" colspan="1">Charlson Comorbidity Index score</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">3.2&#x02005;&#x000b1;&#x02005;2.7</td><td align="center" rowspan="1" colspan="1">3.8&#x02005;&#x000b1;&#x02005;2.9</td><td align="center" rowspan="1" colspan="1">2.5&#x02005;&#x000b1;&#x02005;2.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" colspan="6" rowspan="1">Preoperative laboratory data</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PaCO<sub>2</sub>, mm-Hg</td><td align="center" rowspan="1" colspan="1">348</td><td align="center" rowspan="1" colspan="1">38.6&#x02005;&#x000b1;&#x02005;19.1</td><td align="center" rowspan="1" colspan="1">40.7&#x02005;&#x000b1;&#x02005;22.0</td><td align="center" rowspan="1" colspan="1">36.2&#x02005;&#x000b1;&#x02005;14.7</td><td align="center" rowspan="1" colspan="1">.03</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PH</td><td align="center" rowspan="1" colspan="1">348</td><td align="center" rowspan="1" colspan="1">7.3&#x02005;&#x000b1;&#x02005;0.2</td><td align="center" rowspan="1" colspan="1">7.2&#x02005;&#x000b1;&#x02005;0.2</td><td align="center" rowspan="1" colspan="1">7.3&#x02005;&#x000b1;&#x02005;0.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hemoglobin, g/dL</td><td align="center" rowspan="1" colspan="1">882</td><td align="center" rowspan="1" colspan="1">10.9&#x02005;&#x000b1;&#x02005;2.9</td><td align="center" rowspan="1" colspan="1">10.8&#x02005;&#x000b1;&#x02005;3.1</td><td align="center" rowspan="1" colspan="1">11.0&#x02005;&#x000b1;&#x02005;2.6</td><td align="center" rowspan="1" colspan="1">.25</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;White blood cell, 10<sup>3</sup>/&#x003bc;L</td><td align="center" rowspan="1" colspan="1">874</td><td align="center" rowspan="1" colspan="1">13.6&#x02005;&#x000b1;&#x02005;6.6</td><td align="center" rowspan="1" colspan="1">13.6&#x02005;&#x000b1;&#x02005;7.0</td><td align="center" rowspan="1" colspan="1">13.7&#x02005;&#x000b1;&#x02005;6.0</td><td align="center" rowspan="1" colspan="1">.79</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Platelets, 10<sup>3</sup>/&#x003bc;L</td><td align="center" rowspan="1" colspan="1">877</td><td align="center" rowspan="1" colspan="1">163.5&#x02005;&#x000b1;&#x02005;82.0</td><td align="center" rowspan="1" colspan="1">154.8&#x02005;&#x000b1;&#x02005;81.9</td><td align="center" rowspan="1" colspan="1">173.9&#x02005;&#x000b1;&#x02005;81.0</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Creatinine, mg/dL</td><td align="center" rowspan="1" colspan="1">881</td><td align="center" rowspan="1" colspan="1">2.2&#x02005;&#x000b1;&#x02005;2.1</td><td align="center" rowspan="1" colspan="1">2.4&#x02005;&#x000b1;&#x02005;2.3</td><td align="center" rowspan="1" colspan="1">1.9&#x02005;&#x000b1;&#x02005;1.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ALT, U/L</td><td align="center" rowspan="1" colspan="1">671</td><td align="center" rowspan="1" colspan="1">69.0 (32.0&#x02013;205.0)</td><td align="center" rowspan="1" colspan="1">77.0 (35.0&#x02013;210.0)</td><td align="center" rowspan="1" colspan="1">57.0 (29.0&#x02013;169.0)</td><td align="center" rowspan="1" colspan="1">.02</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;AST, U/L</td><td align="center" rowspan="1" colspan="1">742</td><td align="center" rowspan="1" colspan="1">102.5 (52.0&#x02013;266.0)</td><td align="center" rowspan="1" colspan="1">117.0 (59.0&#x02013;325.0)</td><td align="center" rowspan="1" colspan="1">89.0 (47.5&#x02013;198.5)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total bilirubin, mg/dL</td><td align="center" rowspan="1" colspan="1">654</td><td align="center" rowspan="1" colspan="1">1.5&#x02005;&#x000b1;&#x02005;1.6</td><td align="center" rowspan="1" colspan="1">1.5&#x02005;&#x000b1;&#x02005;1.8</td><td align="center" rowspan="1" colspan="1">1.4&#x02005;&#x000b1;&#x02005;1.4</td><td align="center" rowspan="1" colspan="1">.50</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lactic acid, mg/dL</td><td align="center" rowspan="1" colspan="1">548</td><td align="center" rowspan="1" colspan="1">95.8&#x02005;&#x000b1;&#x02005;64.9</td><td align="center" rowspan="1" colspan="1">112.6&#x02005;&#x000b1;&#x02005;64.1</td><td align="center" rowspan="1" colspan="1">75.9&#x02005;&#x000b1;&#x02005;60.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Troponin I, ng/mL</td><td align="center" rowspan="1" colspan="1">675</td><td align="center" rowspan="1" colspan="1">22.5&#x02005;&#x000b1;&#x02005;46.9</td><td align="center" rowspan="1" colspan="1">24.1&#x02005;&#x000b1;&#x02005;51.0</td><td align="center" rowspan="1" colspan="1">20.5&#x02005;&#x000b1;&#x02005;41.3</td><td align="center" rowspan="1" colspan="1">.32</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Data were presented as frequency (percentage) or mean&#x02005;&#x000b1;&#x02005;standard deviation.</p></fn><fn fn-type="other"><p>ALT = alanine aminotransferase, AST = aspartate aminotransferase, ECMO = extracorporeal membrane oxygenation, PaCO2 = partial pressure of carbon dioxide, VA = veno-arterial.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>
3.3. ECMO-related features</title><p>The most common indications for ECMO were post-cardiotomy shock (36.3%), AMI (27%), ECPR (19.4%), decompensated heart failure (7.2%), myocarditis (6.3%), and VT/VF (3.8%). Compared to patients who died during admission, those who survived to discharge were more likely to have a post-cardiotomy shock (41.7% vs 31.9%), less likely to have ECPR (12.9% vs 24.6%), and had more perioperative treatment with PCI/PTCA (21.8% vs 14.9%) (Table <xref rid="T2" ref-type="table">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>ECMO-related features of patients who underwent VA-ECMO by the survival status at discharge.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Available number</th><th align="center" rowspan="1" colspan="1">Total<break/>(n&#x02005;=&#x02005;899)</th><th align="center" rowspan="1" colspan="1">In-hospital death<break/>(n&#x02005;=&#x02005;496)</th><th align="center" rowspan="1" colspan="1">Survivor to discharge<break/>(n&#x02005;=&#x02005;403)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Indication</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post-cardiotomy shock</td><td align="center" rowspan="6" colspan="1">899</td><td align="center" rowspan="1" colspan="1">326 (36.3)</td><td align="center" rowspan="1" colspan="1">158 (31.9)</td><td align="center" rowspan="1" colspan="1">168 (41.7)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Myocarditis</td><td align="center" rowspan="1" colspan="1">57 (6.3)</td><td align="center" rowspan="1" colspan="1">24 (4.8)</td><td align="center" rowspan="1" colspan="1">33 (8.2)</td><td align="center" rowspan="1" colspan="1">.04</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Acute myocardial infarction</td><td align="center" rowspan="1" colspan="1">243 (27.0)</td><td align="center" rowspan="1" colspan="1">131 (26.4)</td><td align="center" rowspan="1" colspan="1">112 (27.8)</td><td align="center" rowspan="1" colspan="1">.64</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;VT/ VF</td><td align="center" rowspan="1" colspan="1">34 (3.8)</td><td align="center" rowspan="1" colspan="1">23 (4.6)</td><td align="center" rowspan="1" colspan="1">11 (2.7)</td><td align="center" rowspan="1" colspan="1">.14</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Decompensated heart failure</td><td align="center" rowspan="1" colspan="1">65 (7.2)</td><td align="center" rowspan="1" colspan="1">38 (7.7)</td><td align="center" rowspan="1" colspan="1">27 (6.7)</td><td align="center" rowspan="1" colspan="1">.58</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ECPR</td><td align="center" rowspan="1" colspan="1">174 (19.4)</td><td align="center" rowspan="1" colspan="1">122 (24.6)</td><td align="center" rowspan="1" colspan="1">52 (12.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration from admission to ECMO insertion, day</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">4.5&#x02005;&#x000b1;&#x02005;6.2</td><td align="center" rowspan="1" colspan="1">4.6&#x02005;&#x000b1;&#x02005;6.6</td><td align="center" rowspan="1" colspan="1">4.4&#x02005;&#x000b1;&#x02005;5.8</td><td align="center" rowspan="1" colspan="1">.67</td></tr><tr><td align="left" rowspan="1" colspan="1">Flow rate, m<sup>3</sup>/s</td><td align="center" rowspan="1" colspan="1">396</td><td align="center" rowspan="1" colspan="1">3281.9&#x02005;&#x000b1;&#x02005;859.3</td><td align="center" rowspan="1" colspan="1">3250.9&#x02005;&#x000b1;&#x02005;864.4</td><td align="center" rowspan="1" colspan="1">3328.5&#x02005;&#x000b1;&#x02005;852.2</td><td align="center" rowspan="1" colspan="1">.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Turn rate, units</td><td align="center" rowspan="1" colspan="1">307</td><td align="center" rowspan="1" colspan="1">2158.6&#x02005;&#x000b1;&#x02005;577.8</td><td align="center" rowspan="1" colspan="1">2158.4&#x02005;&#x000b1;&#x02005;598.9</td><td align="center" rowspan="1" colspan="1">2158.9&#x02005;&#x000b1;&#x02005;547.2</td><td align="center" rowspan="1" colspan="1">.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Oxygen flow, units</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">4049.6&#x02005;&#x000b1;&#x02005;793.3</td><td align="center" rowspan="1" colspan="1">3999.3&#x02005;&#x000b1;&#x02005;902.3</td><td align="center" rowspan="1" colspan="1">4121.9&#x02005;&#x000b1;&#x02005;610.0</td><td align="center" rowspan="1" colspan="1">.51</td></tr><tr><td align="left" colspan="6" rowspan="1">Peripheral/ central</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Peripheral</td><td align="center" rowspan="2" colspan="1">899</td><td align="center" rowspan="1" colspan="1">878 (97.7)</td><td align="center" rowspan="1" colspan="1">483 (97.4)</td><td align="center" rowspan="1" colspan="1">395 (98.0)</td><td align="center" rowspan="2" colspan="1">.53</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Central</td><td align="center" rowspan="1" colspan="1">21 (2.3)</td><td align="center" rowspan="1" colspan="1">13 (2.6)</td><td align="center" rowspan="1" colspan="1">8 (2.0)</td></tr><tr><td align="left" colspan="6" rowspan="1">Treatment before, during or after ECMO</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IABP</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">346 (38.5)</td><td align="center" rowspan="1" colspan="1">179 (36.1)</td><td align="center" rowspan="1" colspan="1">167 (41.4)</td><td align="center" rowspan="1" colspan="1">.10</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PCI/ PTCA</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">162 (18.0)</td><td align="center" rowspan="1" colspan="1">74 (14.9)</td><td align="center" rowspan="1" colspan="1">88 (21.8)</td><td align="center" rowspan="1" colspan="1">.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CABG</td><td align="center" rowspan="1" colspan="1">899</td><td align="center" rowspan="1" colspan="1">193 (21.5)</td><td align="center" rowspan="1" colspan="1">102 (20.6)</td><td align="center" rowspan="1" colspan="1">91 (22.6)</td><td align="center" rowspan="1" colspan="1">.46</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Data were presented as frequency (percentage) or mean&#x02005;&#x000b1;&#x02005;standard deviation.</p></fn><fn fn-type="other"><p>CABG = coronary artery bypass graft, ECMO = extracorporeal membrane oxygenation, ECPR = extracorporeal cardiopulmonary resuscitation, IABP = intra-aortic balloon pump, PCI = percutaneous coronary intervention, PTCA = percutaneous transluminal coronary angioplasty, VA = veno-arterial, VF = ventricular fibrillation, VT = ventricular tachycardia.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>
3.4. LVEF and all-cause mortality</title><p>The results showed that LVEF significantly improved from ECMO insertion (median: 34%) to before discharge (median: 53%) and the 180<sup>th</sup> day after discharge (median: 56%) (<italic toggle="yes">P</italic> for trend&#x02005;&#x0003c;&#x02005;.01; Fig. <xref rid="F3" ref-type="fig">3</xref>A). According to the analytical framework (Fig. <xref rid="F3" ref-type="fig">3</xref>B), the first analysis showed that the improvement in LVEF from ECMO insertion to before discharge was significantly correlated with a lower mortality rate (<italic toggle="yes">P</italic> for trend&#x02005;&#x0003c;&#x02005;.01; Fig. <xref rid="F4" ref-type="fig">4</xref>A). The second analysis demonstrated that a greater LVEF was significantly correlated with a lower mortality rate (<italic toggle="yes">P</italic> for trend&#x02005;&#x0003c;&#x02005;.01; Fig. <xref rid="F4" ref-type="fig">4</xref>B). The third analysis revealed that the mortality risk of patients who improved (&#x02265;10%, n&#x02005;=&#x02005;25) from before discharge to the 180<sup>th</sup> day after discharge vs those who did not improve (&#x0003c;10%) was not significantly different (<italic toggle="yes">P</italic>&#x02005;=&#x02005;.60; Fig. <xref rid="F4" ref-type="fig">4</xref>C). Finally, the fourth analysis indicated that a greater LVEF on the 180<sup>th</sup> day after discharge was significantly correlated with a lower mortality rate (<italic toggle="yes">P</italic> for trend&#x02005;=&#x02005;.04; Fig. <xref rid="F4" ref-type="fig">4</xref>D).</p><fig position="float" id="F3"><label>Figure 3.</label><caption><p>The LVEF values at ECMO insertion, before discharge and the 180th day after discharge (A) and the analytic framework of the study (B). ECMO = extracorporeal membrane oxygenation, LVEF = left ventricular ejection fraction.</p></caption><graphic xlink:href="medi-104-e42306-g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4.</label><caption><p>The relationship between risk of all-cause mortality and LVEF with different definitions: the improvement from ECMO insertion to before discharge (A), the LVEF value before discharge (B), before discharge to the 180th day after discharge (C), and LVEF at the 180th day after discharge (D). ECMO = extracorporeal membrane oxygenation, LVEF = left ventricular ejection fraction.</p></caption><graphic xlink:href="medi-104-e42306-g004" position="float"/></fig></sec></sec><sec sec-type="discussion"><title>
4. Discussion</title><p>In this multicenter analysis study, we retrospectively evaluated patients with CS supported by VA-ECMO who successfully survived hospital discharge. To date, this was the largest multicenter observational retrospective study of myocardial function in VA-ECMO patients with CS. This was also the first study to provide insights into patients who survived discharge with their cardiac function data at admission, before discharge, and long-term follow-up with survival analysis. We found that percentile improvement in EF between ECMO placement and successful weaning was significantly associated with lower cumulative mortality. Second, the EF value before discharge was significantly associated with better survival. Lastly, the association of low long-term mortality with EF change from discharge to mid-term follow-up and the maximum EF at mid-term follow-up was found to be nonsignificant.</p><p>VA-ECMO acts as a temporary bridge<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>]</sup> for myocardial function recovery or further treatment.<sup>[<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>]</sup> Post-cardiotomy shock develops in around 1% of adult patients who require temporal circulatory mechanical support during or after cardiac surgery with a 63.3% successful weaning rate and 24.8% discharge rate.<sup>[<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>]</sup> Chen et al, previously showed that despite better outcomes in the first year, compared to non-ECMO groups, the ECMO group showed similar outcomes after first year follow-up in patients with post-cardiotomy shock using the same database in our hospital.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> In our study, the most common indication for VA-ECMO was a post-cardiotomy shock, and those who survived until discharge were more likely to have a post-cardiotomy shock as an indication. (41.7% vs 31.9%). This finding is in line with past research.<sup>[<xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref>]</sup></p><p>Echocardiography is crucial in weaning trials and the assessment of cardiac function recovery.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup> While most studies focused on identifying mortality predictors at weaning or discharge, evidence of the short-term and long-term outcomes of VA-ECMO remained limited.</p><p>In another retrospective study using data from our hospital center, a preoperative LVEF&#x02005;&#x0003e;&#x02005;30% was associated with a lower long-term cumulative mortality rate in patients receiving ECMO for post-cardiotomy shock.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> Although Sertic et al, further showed that severe LV dysfunction (LVEF&#x02005;&#x0003c;&#x02005;30%) was identified to be associated with a lower postweaning survival rate, it was limited to the absolute value of LVEF.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> Our study was the first to investigate dynamic changes in LV function during ECMO support and from discharge to mid-term follow-up. We showed an overall improvement in LVEF in patients who survived mid-term follow-up. The major findings of our study suggested that improvements in ejection fraction were strongly associated with favorable long-term survival. An improvement in EF may indicate restored myocardial function. It could serve as a direct monitoring parameter in complex weaning strategies,<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> and for further treatment since these patients have better long-term survival.</p><p>Our study provided further evidence of the impact of EF on long-term survival at different time points. We confirmed the results of past studies that an absolute value of EF&#x02005;&#x0003c;&#x02005;30% before discharge is associated with worse outcomes and found that the EF&#x02005;&#x0003e;&#x02005;50% group fared even better in first-year survival.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup> However, a higher absolute value of the maximum EF at 6 months follow-up was not significantly associated with reduced mortality. Improvements in EF from discharge to 6 months also showed no significance. One possible explanation was that improvement in EF from ECMO placement to before discharge or higher EF at weaning played a more decisive role in deciding mortality, reducing the effect seen on future improvements in EF. Another possibility was that the smaller follow-up group size failed to show significance. It is worth noting that percentile improvement of LVEF during VA-ECMO insertion cannot be inferred as the cause of improved long-term mortality, since worse long-term mortality has also been shown to be associated with other predictive factors, such as indications, duration of VA-ECMO support, diabetes, and previous myocardial infarction.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R19" ref-type="bibr">19</xref>]</sup></p><p>The clinical implications of our findings were 3-fold. <italic toggle="yes">Weaning protocol:</italic> Additional parameters, such as LVEF, aortic velocity-time integral, and lateral mitral annulus peak systolic velocity, should be monitored during the weaning process. Notable improvements in the EF percentile&#x02005;&#x0003e;&#x02005;20%) between ECMO placement and weaning could be a positive indicator, increasing confidence in successful weaning. <italic toggle="yes">Discharge planning:</italic> Patients with low EF at weaning were at higher risk of mortality, necessitating referrals to heart failure specialists and cardiac rehabilitation programs to optimize outcomes. <italic toggle="yes">Post-discharge monitoring:</italic> Early enrollment in heart transplant programs or elective durable VAD therapy could be recommended for select candidates. Close monitoring and follow-up of discharged patients were essential to identify individuals at risk of first-year mortality and to facilitate timely decisions regarding advanced therapies, such as VADs or heart transplants.<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R20" ref-type="bibr">20</xref>]</sup></p><sec><title>
4.1. Limitations</title><p>This study had several limitations. First, limitations common to its retrospective and observational nature may be relevant, including the possibility of a selection bias. Further analyses are required for patients bridged to VADs and heart transplants and for those with indications not of interest. Confounding factors that could affect survival other than directly changing myocardial function render the relationship between survival and EF relative rather than causative. Second, the patient group size in our series could have affected the significance of our results, especially in the analyses involving missing mid-term and long-term EF data due to loss of follow-up or changes in electronic records. Finally, there is a limitation in extending the results to other countries owing to the higher ECPR usage in Taiwan,<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> which lacks records of baseline EF at presentation to the emergency room and lower numbers of VADs and heart transplants.</p></sec></sec><sec><title>
5. Conclusion</title><p>Ejection fraction monitoring at ECMO insertion and before discharge can inform physicians regarding patients&#x02019; long-term outcomes. EF percentile improvement from insertion to hospital discharge and a higher absolute EF value before discharge were associated with lower long-term mortality rates. Studies of other cardiac echocardiography parameters using long-term follow-up data should be performed in future research to validate these findings.</p></sec><sec><title>Acknowledgments</title><p>The authors thank the statistical assistance and wish to acknowledge the support of the Maintenance Project of the Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou for study design and monitoring, data analysis, and interpretation. The authors also thank Alfred Hsing-Fen Lin and Ben Yu-Lin Chou for their assistance with the statistical analysis.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Yu-Ting Cheng, Shao-Wei Chen.</p><p><bold>Data curation:</bold> Cheng-Ta Yang, Yu-Ting Cheng.</p><p><bold>Funding acquisition:</bold> Shao-Wei Chen.</p><p><bold>Investigation:</bold> Cheng-Ta Yang, Yu-Ting Cheng, Shao-Wei Chen.</p><p><bold>Methodology:</bold> Yu-Ting Cheng, Shao-Wei Chen.</p><p><bold>Resources:</bold> Shao-Wei Chen.</p><p><bold>Supervision:</bold> Yu-Ting Cheng, Yi&#x02010;Hsin Chan.</p><p><bold>Writing &#x02013; original draft:</bold> Cheng-Ta Yang.</p><p><bold>Writing &#x02013; review &#x00026; editing:</bold> Cheng-Ta Yang, Yu-Ting Cheng, Yi&#x02010;Hsin Chan, Victor Chien-Chia Wu, Dong-Yi Chen, Kuo-Chun Hung, Fu-Chih Hsiao, Ying-Chang Tung, Chia-Pin Lin, Pao-Hsien Chu, Shao-Wei Chen.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>ALT</term><def><p>alanine aminotransferase</p></def></def-item><def-item><term>AMI</term><def><p>acute myocardial infarction</p></def></def-item><def-item><term>AST</term><def><p>aspartate aminotransferase</p></def></def-item><def-item><term>CABG</term><def><p>coronary artery bypass graft</p></def></def-item><def-item><term>CCI</term><def><p>Charlson comorbidity index</p></def></def-item><def-item><term>CGMH</term><def><p>Chang Gung Memorial Hospitals</p></def></def-item><def-item><term>CGRD</term><def><p>Chang Gung Research Database</p></def></def-item><def-item><term>CS</term><def><p>cardiogenic shock</p></def></def-item><def-item><term>ECMO</term><def><p>extracorporeal membrane oxygenation</p></def></def-item><def-item><term>ECPR</term><def><p>extracorporeal cardiopulmonary resuscitation</p></def></def-item><def-item><term>EF</term><def><p>ejection fraction</p></def></def-item><def-item><term>HF</term><def><p>heart failure</p></def></def-item><def-item><term>IABP</term><def><p>intra-aortic balloon pump</p></def></def-item><def-item><term>LV</term><def><p>left ventricle</p></def></def-item><def-item><term>LVEF</term><def><p>left ventricle ejection fraction</p></def></def-item><def-item><term>PCI</term><def><p>percutaneous coronary intervention</p></def></def-item><def-item><term>PTCA</term><def><p>percutaneous transluminal coronary angioplasty</p></def></def-item><def-item><term>VA-ECMO</term><def><p>veno-arterial-extracorporeal membrane oxygenation</p></def></def-item><def-item><term>VF</term><def><p>ventricular fibrillation</p></def></def-item><def-item><term>VT</term><def><p>ventricular tachycardia</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>This work was supported by a grant from Chang Gung Memorial Hospital, Taiwan CFRPG3N0011(YTC) and CORPG3N0281, CORPG3M0371, CORPG3M0372, CMRPG3L0101, CMRPG3L0102, CMRPG3L0103, CFRPG3M0011, BMRPD95(SWC). This work was also supported by the National Science and Technology Council grant NSTC-112-2314-B-182A-107 (SWC).</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.</p></fn><fn fn-type="other"><p>How to cite this article: Yang C-T, Cheng Y-T, Chan Y-H, Wu VC-C, Chen D-Y, Hung K-C, Hsiao F-C, Tung Y-C, Lin C-P, Chu P-H, Chen S-W. Impact of ejection fraction changes on long-term outcomes in VA-ECMO patients. Medicine 2025;104:20(e42306).</p></fn><fn fn-type="equal"><p>CY and YC contributed to this article equally.</p></fn><fn fn-type="other"><p>This manuscript was previously posted to bioRxiv: doi: <ext-link xlink:href="https://doi.org/10.1101/2023.04.11.23288438" ext-link-type="uri">https://doi.org/10.1101/2023.04.11.23288438</ext-link>.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YS</given-names></name><name><surname>Lin</surname><given-names>JW</given-names></name><name><surname>Yu</surname><given-names>HY</given-names></name><etal/></person-group>. <article-title>Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis.</article-title>
<source>Lancet (London)</source>. <year>2008</year>;<volume>372</volume>:<fpage>554</fpage>&#x02013;<lpage>61</lpage>.</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sertic</surname><given-names>F</given-names></name><name><surname>Bermudez</surname><given-names>C</given-names></name><name><surname>Rame</surname><given-names>JE</given-names></name></person-group>. <article-title>Venoarterial extracorporeal membrane oxygenation as a bridge to recovery or bridge to heart replacement therapy in refractory cardiogenic shock.</article-title>
<source>Curr Heart Fail Rep</source>. <year>2020</year>;<volume>17</volume>:<fpage>341</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">33098525</pub-id>
</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappalardo</surname><given-names>F</given-names></name><name><surname>Pieri</surname><given-names>M</given-names></name><name><surname>Arnaez Corada</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Timing and strategy for weaning from venoarterial ECMO are complex issues.</article-title>
<source>J Cardiothorac Vasc Anesth</source>. <year>2015</year>;<volume>29</volume>:<fpage>906</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">25836952</pub-id>
</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sertic</surname><given-names>F</given-names></name><name><surname>Chavez</surname><given-names>L</given-names></name><name><surname>Diagne</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Predictors of in-hospital mortality and midterm outcomes of patients successfully weaned from venoarterial extracorporeal membrane oxygenation.</article-title>
<source>J Thorac Cardiovasc Surg</source>. <year>2021</year>;<volume>161</volume>:<fpage>666</fpage>&#x02013;<lpage>78.e3</lpage>.<pub-id pub-id-type="pmid">31973895</pub-id>
</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>MY</given-names></name><name><surname>Lin</surname><given-names>PJ</given-names></name><name><surname>Lee</surname><given-names>MY</given-names></name><etal/></person-group>. <article-title>Using extracorporeal life support to resuscitate adult postcardiotomy cardiogenic shock: treatment strategies and predictors of short-term and midterm survival.</article-title>
<source>Resuscitation</source>. <year>2010</year>;<volume>81</volume>:<fpage>1111</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">20627521</pub-id>
</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsing</surname><given-names>AW</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group>. <article-title>Nationwide population science: lessons from the Taiwan National Health Insurance Research Database.</article-title>
<source>JAMA Intern Med</source>. <year>2015</year>;<volume>175</volume>:<fpage>1527</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26192815</pub-id>
</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuhara</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Kurlansky</surname><given-names>PA</given-names></name><name><surname>Naka</surname><given-names>Y</given-names></name><name><surname>Takayama</surname><given-names>H</given-names></name></person-group>. <article-title>Extracorporeal membrane oxygenation as a direct bridge to heart transplantation in adults.</article-title>
<source>J Thorac Cardiovasc Surg</source>. <year>2018</year>;<volume>155</volume>:<fpage>1607</fpage>&#x02013;<lpage>18.e6</lpage>.<pub-id pub-id-type="pmid">29361299</pub-id>
</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherer</surname><given-names>M</given-names></name><name><surname>Moritz</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>S</given-names></name></person-group>. <article-title>The use of extracorporeal membrane oxygenation in patients with therapy refractory cardiogenic shock as a bridge to implantable left ventricular assist device and perioperative right heart support.</article-title>
<source>J Artif Organs</source>. <year>2009</year>;<volume>12</volume>:<fpage>160</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">19894089</pub-id>
</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guglin</surname><given-names>M</given-names></name><name><surname>Zucker</surname><given-names>MJ</given-names></name><name><surname>Bazan</surname><given-names>VM</given-names></name><etal/></person-group>. <article-title>Venoarterial ECMO for adults: JACC scientific expert panel.</article-title>
<source>J Am Coll Cardiol</source>. <year>2019</year>;<volume>73</volume>:<fpage>698</fpage>&#x02013;<lpage>716</lpage>.<pub-id pub-id-type="pmid">30765037</pub-id>
</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouweneel</surname><given-names>DM</given-names></name><name><surname>Schotborgh</surname><given-names>JV</given-names></name><name><surname>Limpens</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis.</article-title>
<source>Intensive Care Med</source>. <year>2016</year>;<volume>42</volume>:<fpage>1922</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">27647331</pub-id>
</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guglin</surname><given-names>M</given-names></name><name><surname>Burchett</surname><given-names>A</given-names></name></person-group>. <article-title>VA-ECMO in cardiogenic shock in adults: indications and outcomes.</article-title>
<source>The VAD Journal</source>. <year>2016</year>;<volume>2</volume>:<fpage>8</fpage>.</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squiers</surname><given-names>JJ</given-names></name><name><surname>Lima</surname><given-names>B</given-names></name><name><surname>DiMaio</surname><given-names>JM</given-names></name></person-group>. <article-title>Contemporary extracorporeal membrane oxygenation therapy in adults: fundamental principles and systematic review of the evidence.</article-title>
<source>J Thorac Cardiovasc Surg</source>. <year>2016</year>;<volume>152</volume>:<fpage>20</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27060027</pub-id>
</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastan</surname><given-names>AJ</given-names></name><name><surname>Dege</surname><given-names>A</given-names></name><name><surname>Mohr</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock.</article-title>
<source>J Thorac Cardiovasc Surg</source>. <year>2010</year>;<volume>139</volume>:<fpage>302</fpage>&#x02013;<lpage>11, 311.e1</lpage>.<pub-id pub-id-type="pmid">20106393</pub-id>
</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SW</given-names></name><name><surname>Tsai</surname><given-names>FC</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><etal/></person-group>. <article-title>Long-term outcomes of extracorporeal membrane oxygenation support for postcardiotomy shock.</article-title>
<source>J Thorac Cardiovasc Surg</source>. <year>2017</year>;<volume>154</volume>:<fpage>469</fpage>&#x02013;<lpage>77.e2</lpage>.<pub-id pub-id-type="pmid">28413074</pub-id>
</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsharkawy</surname><given-names>HA</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Esa</surname><given-names>WAS</given-names></name><name><surname>Sessler</surname><given-names>DI</given-names></name><name><surname>Bashour</surname><given-names>CA</given-names></name></person-group>. <article-title>Outcome in patients who require venoarterial extracorporeal membrane oxygenation support after cardiac surgery.</article-title>
<source>J Cardiothorac Vasc Anesth</source>. <year>2010</year>;<volume>24</volume>:<fpage>946</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">20599396</pub-id>
</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Hou</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Risk factors of in-hospital mortality in adult postcardiotomy cardiogenic shock patients successfully weaned from venoarterial extracorporeal membrane oxygenation.</article-title>
<source>Perfusion</source>. <year>2020</year>;<volume>35</volume>:<fpage>417</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">31854226</pub-id>
</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavarocchi</surname><given-names>NC</given-names></name><name><surname>Pitcher</surname><given-names>HT</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Weaning of extracorporeal membrane oxygenation using continuous hemodynamic transesophageal echocardiography.</article-title>
<source>J Thorac Cardiovasc Surg</source>. <year>2013</year>;<volume>146</volume>:<fpage>1474</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23993027</pub-id>
</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aissaoui</surname><given-names>N</given-names></name><name><surname>El-Banayosy</surname><given-names>A</given-names></name><name><surname>Combes</surname><given-names>A</given-names></name></person-group>. <article-title>How to wean a patient from veno-arterial extracorporeal membrane oxygenation.</article-title>
<source>Intensive Care Med</source>. <year>2015</year>;<volume>41</volume>:<fpage>902</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25619488</pub-id>
</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Gigorro</surname><given-names>R</given-names></name><name><surname>Renes-Carre&#x000f1;o</surname><given-names>E</given-names></name><name><surname>P&#x000e9;rez-Vela</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Soporte mec&#x000e1;nico con membrana de oxigenaci&#x000f3;n extracorp&#x000f3;rea veno-arterial (ECMO-VA): evoluci&#x000f3;n a corto y a largo plazo tras la retirada de la asistencia.</article-title>
<source>Med Intensiva</source>. <year>2017</year>;<volume>41</volume>:<fpage>513</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">28259366</pub-id>
</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagani</surname><given-names>FD</given-names></name><name><surname>Aaronson</surname><given-names>KD</given-names></name><name><surname>Dyke</surname><given-names>DB</given-names></name><name><surname>Wright</surname><given-names>S</given-names></name><name><surname>Swaniker</surname><given-names>F</given-names></name><name><surname>Bartlett</surname><given-names>RH</given-names></name></person-group>. <article-title>Assessment of an extracorporeal life support to LVAD bridge to heart transplant strategy.</article-title>
<source>Ann Thorac Surg</source>. <year>2000</year>;<volume>70</volume>:<fpage>1977</fpage>&#x02013;<lpage>84; discussion 1984</lpage>.<pub-id pub-id-type="pmid">11156106</pub-id>
</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CP</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Wei</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>Extracorporeal membrane oxygenation use, expenditure, and outcomes in Taiwan from 2000 to 2010.</article-title>
<source>J Epidemiol</source>. <year>2015</year>;<volume>25</volume>:<fpage>321</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">25797598</pub-id>
</mixed-citation></ref></ref-list></back></article>